Literature DB >> 23123701

Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.

Emmanuelle A D Schindler1, John A Harvey, Vincent J Aloyo.   

Abstract

The phenethylamine and indoleamine classes of hallucinogens demonstrate distinct pharmacological properties, although they share a serotonin(2A) (5-HT(2A)) receptor mechanism of action (MOA). The 5-HT(2A) receptor signals through phosphatidylinositol (PI) hydrolysis, which is initiated upon activation of phospholipase C (PLC). The role of PI hydrolysis in the effects of hallucinogens remains unclear. In order to better understand the role of PI hydrolysis in the MOA of hallucinogens, the PLC inhibitor, 1-[6-((17β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione (U73122), was used to study the effects of two hallucinogens, the phenethylamine, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), and the indoleamine, lysergic acid diethylamide (LSD). PI hydrolysis was quantified through release of [3H]inositol-4-phosphate from living rabbit frontocortical tissue prisms. Head bobs were counted after hallucinogens were infused into the medial prefrontal cortex (mPFC) of rabbits. Both DOI and LSD stimulated PI hydrolysis in frontocortical tissue through activation of PLC. DOI-stimulated PI hydrolysis was blocked by 5-HT(2A/2C) receptor antagonist, ketanserin, whereas the LSD signal was blocked by 5-HT(2B/2C) receptor antagonist, SB206553. When infused into the mPFC, both DOI- and LSD-elicited head bobs. Pretreatment with U73122 blocked DOI-, but not LSD-elicited head bobs. The two hallucinogens investigated were distinct in their activation of the PI hydrolysis signaling pathway. The serotonergic receptors involved with DOI and LSD signals in frontocortical tissue were different. Furthermore, PLC activation in mPFC was necessary for DOI-elicited head bobs, whereas LSD-elicited head bobs were independent of this pathway. These novel findings urge closer investigation into the intracellular mechanism of action of these unique compounds. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123701      PMCID: PMC3559188          DOI: 10.1016/j.brainres.2012.10.057

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  48 in total

1.  The nature of the binding between LSD and a 5-HT receptor: a possible explanation for hallucinogenic activity.

Authors:  M J Berridge; W T Prince
Journal:  Br J Pharmacol       Date:  1974-06       Impact factor: 8.739

2.  (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.

Authors:  K D Burris; M Breeding; E Sanders-Bush
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

3.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

4.  Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.

Authors:  K D Burris; E Sanders-Bush
Journal:  Mol Pharmacol       Date:  1992-11       Impact factor: 4.436

5.  Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP).

Authors:  P M Callahan; K A Cunningham
Journal:  Eur J Pharmacol       Date:  1994-05-12       Impact factor: 4.432

6.  Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus.

Authors:  E L Barker; K D Burris; E Sanders-Bush
Journal:  Brain Res       Date:  1991-06-28       Impact factor: 3.252

7.  Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.

Authors:  M Rinaldi-Carmona; M Bouaboula; C Congy; F Oury-Donat; J Simiand; D Shire; P Casellas; P Soubrié; J C Brelière; G Le Fur
Journal:  Eur J Pharmacol       Date:  1993-06-15       Impact factor: 4.432

8.  (+/-)-1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane(DOI) and alpha-methyl-5-HT: 5-HT2 receptor agonistic action on phosphatidylinositol metabolism in the rat fronto-cingulate and entorhinal cortex.

Authors:  E Edwards; C R Ashby; R Y Wang
Journal:  Neuropharmacology       Date:  1992-07       Impact factor: 5.250

9.  Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.

Authors:  M Rinaldi-Carmona; C Congy; J Simiand; F Oury-Donat; P Soubrie; J C Breliere; G Le Fur
Journal:  Mol Pharmacol       Date:  1993-01       Impact factor: 4.436

10.  Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.

Authors:  P A Pierce; S J Peroutka
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

View more
  4 in total

1.  Ebselen has lithium-like effects on central 5-HT2A receptor function.

Authors:  I Antoniadou; M Kouskou; T Arsiwala; N Singh; S R Vasudevan; T Fowler; E Cadirci; G C Churchill; T Sharp
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

2.  Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function.

Authors:  Amy J Eshleman; Michael J Forster; Katherine M Wolfrum; Robert A Johnson; Aaron Janowsky; Michael B Gatch
Journal:  Psychopharmacology (Berl)       Date:  2013-10-19       Impact factor: 4.530

Review 3.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

Review 4.  Serotonin toxicity of serotonergic psychedelics.

Authors:  Benjamin Malcolm; Kelan Thomas
Journal:  Psychopharmacology (Berl)       Date:  2021-07-12       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.